-
Welcome Note
Pascal BehrDone
-
Apero and poster presentation
Done
-
Social Activity - Bowling
Done
-
Implementing Live-seq on a triple-negative breast cancer cell line - Session: Single-cell RNA sequencing: Live-seq and biopsies
Margot Le-BotDone
-
The SARS-COV-2 cytoplasmic tail story: Biophysical Approach in the understanding of SARS-CoV tropism
Bhanupriya PanigrahiDone
-
Closing Note
Done
-
FluidFM as an enabling tool in bioelectronics research
Prof. Janos VörösDone
-
Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9 - Session Gene engineering and CRISPR
Dr. Justin AnthonyDone
-
Registration and coffee
Done
-
Registration and coffee
Done
Ph.D. in Biophysics, currently working for the U.S. Department of Commerce, NIST Genome Editing Program.
Staff Scientist Simona Patange simona.patange@nist.gov
NIST, USA
Abstract:
Genome editing is a rapidly emerging biotechnology with the potential to transform many sectors of industry. For genome editing systems to achieve their maximum potential in research and commercial applications, it is critical to develop new measurement capabilities, control materials, and standards for evaluating genome-edited technologies and products (e.g., engineered cells) on their intended purpose. In this talk I give an overview of the U.S NIST Genome Editing Program and our efforts to solve current measurement challenges faced by the genome editing community. Single-cell manipulation and measurement technologies are valuable for increasing confidence in the genome editing process, and I present our use of FluidFM to investigate current measurement questions related to CRISPR/Cas9 formulation and delivery.
